Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMS-D008 in Healthy Adults and Adults Living With Overweight or Obesity
NCT07518589Phase 1Not yet recruiting
- Sponsor
- Shenzhen Kangzhe Biotechnology
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides
01
Overview
Phase 1, randomised, double-blind trial of CMS-D008 in obesity and Overweight (6 arms), sponsored by Shenzhen Kangzhe Biotechnology. Primary endpoints: Change from baseline to each visit point in vital signs, Incidence rate of abnormal findings in comprehensive systemic physical examination and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CMS-D008
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07518589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518589.